late stage tumor tissue Search Results


99
ATCC a549 lung cancer cell
In vitro anti-proliferative activity of the synthesised compounds, CA-4, CA-4P, and taxol against eleven cell lines <xref ref-type= a (IC 50 (µM b ))" width="250" height="auto" />
A549 Lung Cancer Cell, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a549 lung cancer cell/product/ATCC
Average 99 stars, based on 1 article reviews
a549 lung cancer cell - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

96
AMS Biotechnology late stage tumor tissue
In vitro anti-proliferative activity of the synthesised compounds, CA-4, CA-4P, and taxol against eleven cell lines <xref ref-type= a (IC 50 (µM b ))" width="250" height="auto" />
Late Stage Tumor Tissue, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/late stage tumor tissue/product/AMS Biotechnology
Average 96 stars, based on 1 article reviews
late stage tumor tissue - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

90
Hmong National Development gastric cancer
In vitro anti-proliferative activity of the synthesised compounds, CA-4, CA-4P, and taxol against eleven cell lines <xref ref-type= a (IC 50 (µM b ))" width="250" height="auto" />
Gastric Cancer, supplied by Hmong National Development, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gastric cancer/product/Hmong National Development
Average 90 stars, based on 1 article reviews
gastric cancer - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Nanotherapeutics sirna nanotherapy
In vitro anti-proliferative activity of the synthesised compounds, CA-4, CA-4P, and taxol against eleven cell lines <xref ref-type= a (IC 50 (µM b ))" width="250" height="auto" />
Sirna Nanotherapy, supplied by Nanotherapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sirna nanotherapy/product/Nanotherapeutics
Average 90 stars, based on 1 article reviews
sirna nanotherapy - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

pc3  (ATCC)
99
ATCC pc3
DHRS7 expression, subcellular localization, and orientation. (A) Plotted as x-fold over the median value across 84 human tissues, expression data extracted from BioGPS reveals DHRS7 to be highly preferentially expressed in normal prostate (14 extracted tissues shown). (B) Levels of DHRS7 protein in LNCaP and <t>PC3</t> cells determined by Western blot. Numbers on the left indicate molecular weights. (C) Antibody staining for DHRS7 in LNCaP cells reveals a strong nuclear envelope accumulation along with diffuse staining in the ER. Notably, levels are very low in the bottom cell indicating expression variability in the population. Scale bar, 10 µm. (D) A model for DHRS7 transmembrane helices was generated using TMHMM v2.0. (E) Determination of topology using the digitonin assay. Cells expressing a DHRS7-mRFP fusion were permeabilized with either Triton X-100 which removes all membranes or digitonin which preferentially pokes holes in the plasma membrane where cholesterol is abundant. Cells were then fixed and stained with an antibody against mRFP. If the epitope is in the lumen it is masked and so will be inaccessible to the antibody so that there would be less signal from the antibody than from the mRFP. The similar staining pattern indicates the epitope on the C-terminal region of the protein is accessible to the cytoplasm/ nucleoplasm. Scale bar 10 μm.
Pc3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pc3/product/ATCC
Average 99 stars, based on 1 article reviews
pc3 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

90
CH Instruments chi-square test
DHRS7 expression, subcellular localization, and orientation. (A) Plotted as x-fold over the median value across 84 human tissues, expression data extracted from BioGPS reveals DHRS7 to be highly preferentially expressed in normal prostate (14 extracted tissues shown). (B) Levels of DHRS7 protein in LNCaP and <t>PC3</t> cells determined by Western blot. Numbers on the left indicate molecular weights. (C) Antibody staining for DHRS7 in LNCaP cells reveals a strong nuclear envelope accumulation along with diffuse staining in the ER. Notably, levels are very low in the bottom cell indicating expression variability in the population. Scale bar, 10 µm. (D) A model for DHRS7 transmembrane helices was generated using TMHMM v2.0. (E) Determination of topology using the digitonin assay. Cells expressing a DHRS7-mRFP fusion were permeabilized with either Triton X-100 which removes all membranes or digitonin which preferentially pokes holes in the plasma membrane where cholesterol is abundant. Cells were then fixed and stained with an antibody against mRFP. If the epitope is in the lumen it is masked and so will be inaccessible to the antibody so that there would be less signal from the antibody than from the mRFP. The similar staining pattern indicates the epitope on the C-terminal region of the protein is accessible to the cytoplasm/ nucleoplasm. Scale bar 10 μm.
Chi Square Test, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chi-square test/product/CH Instruments
Average 90 stars, based on 1 article reviews
chi-square test - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

99
ATCC late stage metastatic prostate cancer cells
DHRS7 expression, subcellular localization, and orientation. (A) Plotted as x-fold over the median value across 84 human tissues, expression data extracted from BioGPS reveals DHRS7 to be highly preferentially expressed in normal prostate (14 extracted tissues shown). (B) Levels of DHRS7 protein in LNCaP and <t>PC3</t> cells determined by Western blot. Numbers on the left indicate molecular weights. (C) Antibody staining for DHRS7 in LNCaP cells reveals a strong nuclear envelope accumulation along with diffuse staining in the ER. Notably, levels are very low in the bottom cell indicating expression variability in the population. Scale bar, 10 µm. (D) A model for DHRS7 transmembrane helices was generated using TMHMM v2.0. (E) Determination of topology using the digitonin assay. Cells expressing a DHRS7-mRFP fusion were permeabilized with either Triton X-100 which removes all membranes or digitonin which preferentially pokes holes in the plasma membrane where cholesterol is abundant. Cells were then fixed and stained with an antibody against mRFP. If the epitope is in the lumen it is masked and so will be inaccessible to the antibody so that there would be less signal from the antibody than from the mRFP. The similar staining pattern indicates the epitope on the C-terminal region of the protein is accessible to the cytoplasm/ nucleoplasm. Scale bar 10 μm.
Late Stage Metastatic Prostate Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/late stage metastatic prostate cancer cells/product/ATCC
Average 99 stars, based on 1 article reviews
late stage metastatic prostate cancer cells - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

90
China Pharmaceuticals Inc late-stage metastatic breast cancer
DHRS7 expression, subcellular localization, and orientation. (A) Plotted as x-fold over the median value across 84 human tissues, expression data extracted from BioGPS reveals DHRS7 to be highly preferentially expressed in normal prostate (14 extracted tissues shown). (B) Levels of DHRS7 protein in LNCaP and <t>PC3</t> cells determined by Western blot. Numbers on the left indicate molecular weights. (C) Antibody staining for DHRS7 in LNCaP cells reveals a strong nuclear envelope accumulation along with diffuse staining in the ER. Notably, levels are very low in the bottom cell indicating expression variability in the population. Scale bar, 10 µm. (D) A model for DHRS7 transmembrane helices was generated using TMHMM v2.0. (E) Determination of topology using the digitonin assay. Cells expressing a DHRS7-mRFP fusion were permeabilized with either Triton X-100 which removes all membranes or digitonin which preferentially pokes holes in the plasma membrane where cholesterol is abundant. Cells were then fixed and stained with an antibody against mRFP. If the epitope is in the lumen it is masked and so will be inaccessible to the antibody so that there would be less signal from the antibody than from the mRFP. The similar staining pattern indicates the epitope on the C-terminal region of the protein is accessible to the cytoplasm/ nucleoplasm. Scale bar 10 μm.
Late Stage Metastatic Breast Cancer, supplied by China Pharmaceuticals Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/late-stage metastatic breast cancer/product/China Pharmaceuticals Inc
Average 90 stars, based on 1 article reviews
late-stage metastatic breast cancer - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Pfizer Inc products for treatment of early and late stage breast cancer
DHRS7 expression, subcellular localization, and orientation. (A) Plotted as x-fold over the median value across 84 human tissues, expression data extracted from BioGPS reveals DHRS7 to be highly preferentially expressed in normal prostate (14 extracted tissues shown). (B) Levels of DHRS7 protein in LNCaP and <t>PC3</t> cells determined by Western blot. Numbers on the left indicate molecular weights. (C) Antibody staining for DHRS7 in LNCaP cells reveals a strong nuclear envelope accumulation along with diffuse staining in the ER. Notably, levels are very low in the bottom cell indicating expression variability in the population. Scale bar, 10 µm. (D) A model for DHRS7 transmembrane helices was generated using TMHMM v2.0. (E) Determination of topology using the digitonin assay. Cells expressing a DHRS7-mRFP fusion were permeabilized with either Triton X-100 which removes all membranes or digitonin which preferentially pokes holes in the plasma membrane where cholesterol is abundant. Cells were then fixed and stained with an antibody against mRFP. If the epitope is in the lumen it is masked and so will be inaccessible to the antibody so that there would be less signal from the antibody than from the mRFP. The similar staining pattern indicates the epitope on the C-terminal region of the protein is accessible to the cytoplasm/ nucleoplasm. Scale bar 10 μm.
Products For Treatment Of Early And Late Stage Breast Cancer, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/products for treatment of early and late stage breast cancer/product/Pfizer Inc
Average 90 stars, based on 1 article reviews
products for treatment of early and late stage breast cancer - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

dld 1  (ATCC)
99
ATCC dld 1
DHRS7 expression, subcellular localization, and orientation. (A) Plotted as x-fold over the median value across 84 human tissues, expression data extracted from BioGPS reveals DHRS7 to be highly preferentially expressed in normal prostate (14 extracted tissues shown). (B) Levels of DHRS7 protein in LNCaP and <t>PC3</t> cells determined by Western blot. Numbers on the left indicate molecular weights. (C) Antibody staining for DHRS7 in LNCaP cells reveals a strong nuclear envelope accumulation along with diffuse staining in the ER. Notably, levels are very low in the bottom cell indicating expression variability in the population. Scale bar, 10 µm. (D) A model for DHRS7 transmembrane helices was generated using TMHMM v2.0. (E) Determination of topology using the digitonin assay. Cells expressing a DHRS7-mRFP fusion were permeabilized with either Triton X-100 which removes all membranes or digitonin which preferentially pokes holes in the plasma membrane where cholesterol is abundant. Cells were then fixed and stained with an antibody against mRFP. If the epitope is in the lumen it is masked and so will be inaccessible to the antibody so that there would be less signal from the antibody than from the mRFP. The similar staining pattern indicates the epitope on the C-terminal region of the protein is accessible to the cytoplasm/ nucleoplasm. Scale bar 10 μm.
Dld 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld 1/product/ATCC
Average 99 stars, based on 1 article reviews
dld 1 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

90
GraphPad Software Inc graphpad prism software
DHRS7 expression, subcellular localization, and orientation. (A) Plotted as x-fold over the median value across 84 human tissues, expression data extracted from BioGPS reveals DHRS7 to be highly preferentially expressed in normal prostate (14 extracted tissues shown). (B) Levels of DHRS7 protein in LNCaP and <t>PC3</t> cells determined by Western blot. Numbers on the left indicate molecular weights. (C) Antibody staining for DHRS7 in LNCaP cells reveals a strong nuclear envelope accumulation along with diffuse staining in the ER. Notably, levels are very low in the bottom cell indicating expression variability in the population. Scale bar, 10 µm. (D) A model for DHRS7 transmembrane helices was generated using TMHMM v2.0. (E) Determination of topology using the digitonin assay. Cells expressing a DHRS7-mRFP fusion were permeabilized with either Triton X-100 which removes all membranes or digitonin which preferentially pokes holes in the plasma membrane where cholesterol is abundant. Cells were then fixed and stained with an antibody against mRFP. If the epitope is in the lumen it is masked and so will be inaccessible to the antibody so that there would be less signal from the antibody than from the mRFP. The similar staining pattern indicates the epitope on the C-terminal region of the protein is accessible to the cytoplasm/ nucleoplasm. Scale bar 10 μm.
Graphpad Prism Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphpad prism software/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
graphpad prism software - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Jackson Laboratory irfp + /luc + 4t1 cells
Identification of small, occult lesions with FIGS. Color and 800 nm images were obtained during FIGS with the Lab-FLARE RP1 FIGSS. Resected tissues were imaged with the Pearl Trilogy Small Animal Imaging System to confirm presence of tumor with <t>iRFP</t> and 800 nm fluorescence. a,b Red boxes and arrows indicate tissues resected with NanoICG guidance. c Imaging was analyzed with Image Studio software with which tumor areas were calculated. H&E-stained sections of resected tissues were analyzed by a board-certified pathologist. Primary tumor from d the NanoICG group was recognized as tumor (main image: 400×, scale bar = 20 μm; inset image: 40×, scale bar = 200 μm; green arrow indicates area of 400× image). Representative examples of e small, occult lesions that were classified as “tumor-positive” (main image: 400×, scale bar = 20 μm; inset image: 100×, scale bar = 100 μm; green arrow indicates area of 400× image) or f “tumor-negative” (100×, scale bar = 100 μm). Color bar values are reported in AU.
Irfp + /Luc + 4t1 Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/irfp + /luc + 4t1 cells/product/Jackson Laboratory
Average 90 stars, based on 1 article reviews
irfp + /luc + 4t1 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


In vitro anti-proliferative activity of the synthesised compounds, CA-4, CA-4P, and taxol against eleven cell lines <xref ref-type= a (IC 50 (µM b ))" width="100%" height="100%">

Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Article Title: Synthesis and characterisation of ( Z )-styrylbenzene derivatives as potential selective anticancer agents

doi: 10.1080/14756366.2018.1513925

Figure Lengend Snippet: In vitro anti-proliferative activity of the synthesised compounds, CA-4, CA-4P, and taxol against eleven cell lines a (IC 50 (µM b ))

Article Snippet: MGC-803 late-stage differentiation gastric cancer cell, A549 lung cancer cell, HepG2 hepatoma cell, AGS gastric cancer cell, BEL-7402 liver cancer cell, HCT-116 colorectal cancer cell, HeLa cervical cancer cell, SGC-7901 early differentiation gastric cancer cell, L-02 normal liver cell, MCF-7 breast cancer cell, and MCF-10A normal breast cell were initially purchased from American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: In Vitro, Activity Assay

Selectivity index values of compounds relative to the effects on normal cell L-02 or MCF-10A cells.

Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Article Title: Synthesis and characterisation of ( Z )-styrylbenzene derivatives as potential selective anticancer agents

doi: 10.1080/14756366.2018.1513925

Figure Lengend Snippet: Selectivity index values of compounds relative to the effects on normal cell L-02 or MCF-10A cells.

Article Snippet: MGC-803 late-stage differentiation gastric cancer cell, A549 lung cancer cell, HepG2 hepatoma cell, AGS gastric cancer cell, BEL-7402 liver cancer cell, HCT-116 colorectal cancer cell, HeLa cervical cancer cell, SGC-7901 early differentiation gastric cancer cell, L-02 normal liver cell, MCF-7 breast cancer cell, and MCF-10A normal breast cell were initially purchased from American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques:

DHRS7 expression, subcellular localization, and orientation. (A) Plotted as x-fold over the median value across 84 human tissues, expression data extracted from BioGPS reveals DHRS7 to be highly preferentially expressed in normal prostate (14 extracted tissues shown). (B) Levels of DHRS7 protein in LNCaP and PC3 cells determined by Western blot. Numbers on the left indicate molecular weights. (C) Antibody staining for DHRS7 in LNCaP cells reveals a strong nuclear envelope accumulation along with diffuse staining in the ER. Notably, levels are very low in the bottom cell indicating expression variability in the population. Scale bar, 10 µm. (D) A model for DHRS7 transmembrane helices was generated using TMHMM v2.0. (E) Determination of topology using the digitonin assay. Cells expressing a DHRS7-mRFP fusion were permeabilized with either Triton X-100 which removes all membranes or digitonin which preferentially pokes holes in the plasma membrane where cholesterol is abundant. Cells were then fixed and stained with an antibody against mRFP. If the epitope is in the lumen it is masked and so will be inaccessible to the antibody so that there would be less signal from the antibody than from the mRFP. The similar staining pattern indicates the epitope on the C-terminal region of the protein is accessible to the cytoplasm/ nucleoplasm. Scale bar 10 μm.

Journal: bioRxiv

Article Title: Estradiol propionate reduction of nuclear size in prostate cancer lines lacking DHRS7 suggests DHRS7 absence as a biomarker for the effectiveness of estrogen therapy

doi: 10.1101/2023.09.18.558190

Figure Lengend Snippet: DHRS7 expression, subcellular localization, and orientation. (A) Plotted as x-fold over the median value across 84 human tissues, expression data extracted from BioGPS reveals DHRS7 to be highly preferentially expressed in normal prostate (14 extracted tissues shown). (B) Levels of DHRS7 protein in LNCaP and PC3 cells determined by Western blot. Numbers on the left indicate molecular weights. (C) Antibody staining for DHRS7 in LNCaP cells reveals a strong nuclear envelope accumulation along with diffuse staining in the ER. Notably, levels are very low in the bottom cell indicating expression variability in the population. Scale bar, 10 µm. (D) A model for DHRS7 transmembrane helices was generated using TMHMM v2.0. (E) Determination of topology using the digitonin assay. Cells expressing a DHRS7-mRFP fusion were permeabilized with either Triton X-100 which removes all membranes or digitonin which preferentially pokes holes in the plasma membrane where cholesterol is abundant. Cells were then fixed and stained with an antibody against mRFP. If the epitope is in the lumen it is masked and so will be inaccessible to the antibody so that there would be less signal from the antibody than from the mRFP. The similar staining pattern indicates the epitope on the C-terminal region of the protein is accessible to the cytoplasm/ nucleoplasm. Scale bar 10 μm.

Article Snippet: PC3 (late-stage prostate cancer line, ATCC CRL-1435), PC3-H2B-RFP (stable plasmid integration in PC3), and HT1080 fibrosarcoma cell lines were grown in DMEM, 10% fetal bovine serum (FBS).

Techniques: Expressing, Western Blot, Staining, Generated, Clinical Proteomics, Membrane

DHRS7 can direct nuclear size changes in prostate cancer cells. (A) Protein levels of DHRS7 by Western before and after siRNA knockdown (25 nM) in LNCaP cells. Numbers on the left indicate molecular weights. (B) Whisker-scatterplot chart showing quantification of volume reconstructions for ∼100 LNCaP cells knocked down for DHRS7 shows its loss resulted in increased nuclear size. (C) Whisker-scatterplot chart showing the quantification of volume reconstructions for ∼100 PC3 and HT1080 cells with or without exogeneous DHRS7 expression as indicated. Exogenous expression of DHRS7 in late-stage PCa PC3 cells yields decreased nuclear size. All statistical analyses were performed with unpaired t-test with Welch’s correction: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

Journal: bioRxiv

Article Title: Estradiol propionate reduction of nuclear size in prostate cancer lines lacking DHRS7 suggests DHRS7 absence as a biomarker for the effectiveness of estrogen therapy

doi: 10.1101/2023.09.18.558190

Figure Lengend Snippet: DHRS7 can direct nuclear size changes in prostate cancer cells. (A) Protein levels of DHRS7 by Western before and after siRNA knockdown (25 nM) in LNCaP cells. Numbers on the left indicate molecular weights. (B) Whisker-scatterplot chart showing quantification of volume reconstructions for ∼100 LNCaP cells knocked down for DHRS7 shows its loss resulted in increased nuclear size. (C) Whisker-scatterplot chart showing the quantification of volume reconstructions for ∼100 PC3 and HT1080 cells with or without exogeneous DHRS7 expression as indicated. Exogenous expression of DHRS7 in late-stage PCa PC3 cells yields decreased nuclear size. All statistical analyses were performed with unpaired t-test with Welch’s correction: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

Article Snippet: PC3 (late-stage prostate cancer line, ATCC CRL-1435), PC3-H2B-RFP (stable plasmid integration in PC3), and HT1080 fibrosarcoma cell lines were grown in DMEM, 10% fetal bovine serum (FBS).

Techniques: Western Blot, Knockdown, Whisker Assay, Expressing

Medium-throughput screen for compounds decreasing nuclear size in PC3 cells. (A) Screening approach. Drug-treated PC3 cells stably expressing H2B-RFP to determine nuclear size were stained after fixation with CellMask Deep Red dye to determine the total cell area. (B) Replicate screens of plate 6 from the Microsource Spectrum library (compounds listed on Table 1, concentration: 10 μM). Nuclear size (vertical axis) was averaged over a total of 350-4,000 cells per well (horizontal axis). A1/A12, B1/B12 … G1/G12: DMSO controls. Estradiol propionate (EP) is indicated (red circles). Nuclear size reduction by at least 20% was statistically significant (p<0.001, Wilcoxson rank test). (C) Molecular structures of estradiol (top) and EP (bottom). (D) Characteristic images of EP (left) and estradiol benzoate (right)-treated cells (blue: H2B-RFP nuclear signal; red: CellMask Deep Red cytosolic signal).

Journal: bioRxiv

Article Title: Estradiol propionate reduction of nuclear size in prostate cancer lines lacking DHRS7 suggests DHRS7 absence as a biomarker for the effectiveness of estrogen therapy

doi: 10.1101/2023.09.18.558190

Figure Lengend Snippet: Medium-throughput screen for compounds decreasing nuclear size in PC3 cells. (A) Screening approach. Drug-treated PC3 cells stably expressing H2B-RFP to determine nuclear size were stained after fixation with CellMask Deep Red dye to determine the total cell area. (B) Replicate screens of plate 6 from the Microsource Spectrum library (compounds listed on Table 1, concentration: 10 μM). Nuclear size (vertical axis) was averaged over a total of 350-4,000 cells per well (horizontal axis). A1/A12, B1/B12 … G1/G12: DMSO controls. Estradiol propionate (EP) is indicated (red circles). Nuclear size reduction by at least 20% was statistically significant (p<0.001, Wilcoxson rank test). (C) Molecular structures of estradiol (top) and EP (bottom). (D) Characteristic images of EP (left) and estradiol benzoate (right)-treated cells (blue: H2B-RFP nuclear signal; red: CellMask Deep Red cytosolic signal).

Article Snippet: PC3 (late-stage prostate cancer line, ATCC CRL-1435), PC3-H2B-RFP (stable plasmid integration in PC3), and HT1080 fibrosarcoma cell lines were grown in DMEM, 10% fetal bovine serum (FBS).

Techniques: Stable Transfection, Expressing, Staining, Concentration Assay

Estradiol propionate only corrects the cancer nuclear size defect in the absence of DHRS7. (A-D) Whisker-scatterplot charts showing the quantification of nuclear volume in ∼100 cells in presence of the indicated concentrations of estradiol propionate (EP). (A) Wild-type LNCaP cells. (B) LNCaP cells with siRNA-mediated DHRS7 knockdown. (C) Wild-type PC3 cells. (D) PC3 cells with exogenously restored DHRS7 expression. All statistical analyses were performed with unpaired t-test with Welch’s correction: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

Journal: bioRxiv

Article Title: Estradiol propionate reduction of nuclear size in prostate cancer lines lacking DHRS7 suggests DHRS7 absence as a biomarker for the effectiveness of estrogen therapy

doi: 10.1101/2023.09.18.558190

Figure Lengend Snippet: Estradiol propionate only corrects the cancer nuclear size defect in the absence of DHRS7. (A-D) Whisker-scatterplot charts showing the quantification of nuclear volume in ∼100 cells in presence of the indicated concentrations of estradiol propionate (EP). (A) Wild-type LNCaP cells. (B) LNCaP cells with siRNA-mediated DHRS7 knockdown. (C) Wild-type PC3 cells. (D) PC3 cells with exogenously restored DHRS7 expression. All statistical analyses were performed with unpaired t-test with Welch’s correction: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

Article Snippet: PC3 (late-stage prostate cancer line, ATCC CRL-1435), PC3-H2B-RFP (stable plasmid integration in PC3), and HT1080 fibrosarcoma cell lines were grown in DMEM, 10% fetal bovine serum (FBS).

Techniques: Whisker Assay, Knockdown, Expressing

DHRS7 dehydrogenase activity is likely required for its effects on nuclear size. (A) Sequence alignment of DHRS7 against 11β-HDS-B1 and 17-β-HDS-1. The mutated arginine (R82 in DHRS7) is highlighted in blue while residues conserved are in green and conservation of amino acid functionality is indicated in yellow. (B) Structural prediction for DHRS7 generated with the Phyre2 web server, www.sbg.bio.ic.ac.uk/phyre2 /, using human 11β-HDSB1 - PDB 2ILT 1BHS. (C-D) Whisker-scatterplot charts showing the quantification of nuclear volume in ∽100 PC3 cells expressing DHRS7 either wild-type or R82E (C) or PC3 cells expressing DHRS7 R82E mutant in presence of the indicated concentrations of estradiol propionate (EP) (D). All statistical analyses were performed using unpaired t-test with Welch’s correction: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

Journal: bioRxiv

Article Title: Estradiol propionate reduction of nuclear size in prostate cancer lines lacking DHRS7 suggests DHRS7 absence as a biomarker for the effectiveness of estrogen therapy

doi: 10.1101/2023.09.18.558190

Figure Lengend Snippet: DHRS7 dehydrogenase activity is likely required for its effects on nuclear size. (A) Sequence alignment of DHRS7 against 11β-HDS-B1 and 17-β-HDS-1. The mutated arginine (R82 in DHRS7) is highlighted in blue while residues conserved are in green and conservation of amino acid functionality is indicated in yellow. (B) Structural prediction for DHRS7 generated with the Phyre2 web server, www.sbg.bio.ic.ac.uk/phyre2 /, using human 11β-HDSB1 - PDB 2ILT 1BHS. (C-D) Whisker-scatterplot charts showing the quantification of nuclear volume in ∽100 PC3 cells expressing DHRS7 either wild-type or R82E (C) or PC3 cells expressing DHRS7 R82E mutant in presence of the indicated concentrations of estradiol propionate (EP) (D). All statistical analyses were performed using unpaired t-test with Welch’s correction: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

Article Snippet: PC3 (late-stage prostate cancer line, ATCC CRL-1435), PC3-H2B-RFP (stable plasmid integration in PC3), and HT1080 fibrosarcoma cell lines were grown in DMEM, 10% fetal bovine serum (FBS).

Techniques: Activity Assay, Sequencing, Structural Proteomics, Generated, Whisker Assay, Expressing, Mutagenesis

Identification of small, occult lesions with FIGS. Color and 800 nm images were obtained during FIGS with the Lab-FLARE RP1 FIGSS. Resected tissues were imaged with the Pearl Trilogy Small Animal Imaging System to confirm presence of tumor with iRFP and 800 nm fluorescence. a,b Red boxes and arrows indicate tissues resected with NanoICG guidance. c Imaging was analyzed with Image Studio software with which tumor areas were calculated. H&E-stained sections of resected tissues were analyzed by a board-certified pathologist. Primary tumor from d the NanoICG group was recognized as tumor (main image: 400×, scale bar = 20 μm; inset image: 40×, scale bar = 200 μm; green arrow indicates area of 400× image). Representative examples of e small, occult lesions that were classified as “tumor-positive” (main image: 400×, scale bar = 20 μm; inset image: 100×, scale bar = 100 μm; green arrow indicates area of 400× image) or f “tumor-negative” (100×, scale bar = 100 μm). Color bar values are reported in AU.

Journal: Molecular imaging and biology

Article Title: Nanoparticle Formulation of Indocyanine Green Improves Image-Guided Surgery in a Murine Model of Breast Cancer

doi: 10.1007/s11307-019-01462-y

Figure Lengend Snippet: Identification of small, occult lesions with FIGS. Color and 800 nm images were obtained during FIGS with the Lab-FLARE RP1 FIGSS. Resected tissues were imaged with the Pearl Trilogy Small Animal Imaging System to confirm presence of tumor with iRFP and 800 nm fluorescence. a,b Red boxes and arrows indicate tissues resected with NanoICG guidance. c Imaging was analyzed with Image Studio software with which tumor areas were calculated. H&E-stained sections of resected tissues were analyzed by a board-certified pathologist. Primary tumor from d the NanoICG group was recognized as tumor (main image: 400×, scale bar = 20 μm; inset image: 40×, scale bar = 200 μm; green arrow indicates area of 400× image). Representative examples of e small, occult lesions that were classified as “tumor-positive” (main image: 400×, scale bar = 20 μm; inset image: 100×, scale bar = 100 μm; green arrow indicates area of 400× image) or f “tumor-negative” (100×, scale bar = 100 μm). Color bar values are reported in AU.

Article Snippet: Tumor models were established by implanting 2.5 × 10 4 (early-stage breast tumor study) or 2.0 × 10 5 (late stage breast tumor) iRFP + /luc + 4T1 cells suspended in 100 μl 1:1 growth media:Matrigel (Corning) into the right mammary fat pads of 8 week-old female BALB/c mice (Jackson Laboratory; Bar Harbor, ME).

Techniques: Imaging, Fluorescence, Software, Staining